Temporal progression of kainic acid induced neuronal and myelin degeneration in the rat forebrain

被引:123
作者
Hopkins, KJ [1 ]
Wang, GJ [1 ]
Schmued, LC [1 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Jefferson, AR 72079 USA
关键词
kainic acid; excitotoxin; Fluoro-Jade; black-gold; brain pathology;
D O I
10.1016/S0006-8993(00)02137-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The excitatory amino acid glutamate has been implicated in the neurodegeneration associated with several different central nervous system diseases. Treatment with kainic acid (KA), a glutamate analog known to activate the AMPA/KA subtype of glutamate receptor, has been widely used as a model of epilepsy. Long term temporal studies of its neuropathological effects, however, are lacking. In this study, two techniques were used to directly visualize and characterize the neuropathology that occurred over a 2-month period following KA-induced status epilepticus in adult. female Sprague-Dawley rats. Post-injection survival was 2, 4, 8 h, 2 days, 2 weeks, or 2 months. Labeling with Fluoro-Jade B (FJB), a fluorescent green dye that labels the cell body, dendrites, axons and axon terminals of degenerating neurons, was observed within the cortex, hippocampus, thalamus, basal ganglia, and amygdala by 4 h post-treatment. The highest level of labeling was seen in the piriform cortex, hippocampus, and thalamus. Myelin changes in the rat forebrain following KA treatment were also examined using the myelin-specific Black-Gold (BG) stain, Varicose myelinated fibers were observed in the same regions as FJB positive neurons, although these changes were evident by the 2-h survival time-point. Both stains showed a temporal progression of brain damage throughout the affected areas. By 2 months post-treatment, few degenerating neurons could be detected and abnormal myelin was absent in most regions. As myelin chan,aes can be seen prior to neuronal degeneration, and oligodendrocytes express functional AMPA/kainate-type glutamate receptors, the neurodegeneration and myelin pathologies may occur as independent events. Thus, researchers should consider the temporal and multiple effects of kainic acid to optimize conditions for their endpoint of interest when designing experiments. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:69 / 80
页数:12
相关论文
共 15 条
[1]   ELECTROGRAPHIC, CLINICAL AND PATHOLOGICAL ALTERATIONS FOLLOWING SYSTEMIC ADMINISTRATION OF KAINIC ACID, BICUCULLINE OR PENTETRAZOLE - METABOLIC MAPPING USING THE DEOXYGLUCOSE METHOD WITH SPECIAL REFERENCE TO THE PATHOLOGY OF EPILEPSY [J].
BENARI, Y ;
TREMBLAY, E ;
RICHE, D ;
GHILINI, G ;
NAQUET, R .
NEUROSCIENCE, 1981, 6 (07) :1361-1391
[2]  
COYLE JT, 1987, CIBA F SYMP, V126, P186
[3]   AUTORADIOGRAPHIC ANALYSIS OF [H-3] KAINIC ACID BINDING IN PRIMATE BRAIN [J].
CROSS, AJ ;
SKAN, WJ ;
SLATER, P ;
MITCHELL, IJ ;
CROSSMAN, AR .
JOURNAL OF RECEPTOR RESEARCH, 1987, 7 (06) :775-797
[4]   EFFECTS OF ANESTHETICS, ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON KAINIC ACID-INDUCED LOCAL AND DISTAL NEURONAL LOSS [J].
LEES, GJ .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1992, 108 (02) :221-228
[5]   Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter [J].
Li, SX ;
Stys, PK .
JOURNAL OF NEUROSCIENCE, 2000, 20 (03) :1190-1198
[6]   Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity [J].
McDonald, JW ;
Althomsons, SP ;
Hyrc, KL ;
Choi, DW ;
Goldberg, MP .
NATURE MEDICINE, 1998, 4 (03) :291-297
[7]   THE REVENGE OF THE KAINATE RECEPTOR [J].
MILLER, RJ .
TRENDS IN NEUROSCIENCES, 1991, 14 (11) :477-479
[8]   THE DISTRIBUTION OF [H-3] KAINIC ACID BINDING-SITES IN RAT CNS AS DETERMINED BY AUTORADIOGRAPHY [J].
MONAGHAN, DT ;
COTMAN, CW .
BRAIN RESEARCH, 1982, 252 (01) :91-100
[9]   KAINIC ACID - POWERFUL NEUROTOXIC ANALOG OF GLUTAMATE [J].
OLNEY, JW ;
RHEE, V ;
HO, OL .
BRAIN RESEARCH, 1974, 77 (03) :507-512
[10]   Function in neurotoxicity: Index of effect and also determinant of vulnerability [J].
Ray, DE .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1997, 24 (11) :857-860